troglitazone has been researched along with Diabetes, Gestational in 7 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Diabetes, Gestational: Diabetes mellitus induced by PREGNANCY but resolved at the end of pregnancy. It does not include previously diagnosed diabetics who become pregnant (PREGNANCY IN DIABETICS). Gestational diabetes usually develops in late pregnancy when insulin antagonistic hormones peaks leading to INSULIN RESISTANCE; GLUCOSE INTOLERANCE; and HYPERGLYCEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Oral glucose tolerance tests (OGTTs) and frequently sampled intravenous glucose tolerance tests (FSIGTs) were conducted on Latino women with impaired glucose tolerance and a history of gestational diabetes before and after 12 weeks of treatment with 400 mg/day troglitazone (n = 13) or placebo (n = 12)." | 5.09 | Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Xiang, AH, 2000) |
| "We conducted a randomized placebo-controlled study to determine the effects of the thiazolidinedione compound troglitazone on whole-body insulin sensitivity (SI), pancreatic beta-cell function, and glucose tolerance in 42 Latino women with impaired glucose tolerance (IGT) and a history of gestational diabetes mellitus (GDM), characteristics that carry an 80% risk of developing NIDDM within 5 years." | 5.08 | Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM. ( Azen, S; Berkowitz, K; Buchanan, TA; Dunn, ME; Goico, J; Kjos, SL; Marroquin, A; Peters, R; Xiang, A, 1996) |
| "Treatment with troglitazone delayed or prevented the onset of type 2 diabetes in high-risk Hispanic women." | 2.70 | Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. ( Azen, SP; Berkowitz, K; Buchanan, TA; Goico, J; Hodis, HN; Kjos, SL; Marroquin, A; Ochoa, C; Peters, RK; Tan, S; Xiang, AH, 2002) |
| "Women with a history of gestational diabetes mellitus (GDM) are at increased risk of future development of type 2 diabetes." | 1.39 | Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score. ( Cho, NH; Cho, YM; Choi, SH; Jang, HC; Jung, HS; Kim, K; Kim, SY; Kwak, SH; Lim, S; Park, KS, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kwak, SH | 1 |
| Choi, SH | 1 |
| Kim, K | 1 |
| Jung, HS | 1 |
| Cho, YM | 1 |
| Lim, S | 1 |
| Cho, NH | 1 |
| Kim, SY | 1 |
| Park, KS | 1 |
| Jang, HC | 1 |
| Buchanan, TA | 4 |
| Xiang, AH | 3 |
| Peters, RK | 3 |
| Kjos, SL | 4 |
| Marroquin, A | 4 |
| Goico, J | 4 |
| Ochoa, C | 3 |
| Tan, S | 1 |
| Berkowitz, K | 3 |
| Hodis, HN | 2 |
| Azen, SP | 2 |
| Solignac, M | 1 |
| Schröder, AK | 1 |
| Tauchert, S | 1 |
| Ortmann, O | 1 |
| Diedrich, K | 1 |
| Weiss, JM | 1 |
| Kawakubo, M | 1 |
| Liu, CR | 1 |
| Liu, CH | 1 |
| Peters, R | 1 |
| Dunn, ME | 1 |
| Xiang, A | 1 |
| Azen, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Effect of Gain on Closed-Loop Insulin[NCT02065895] | 8 participants (Actual) | Interventional | 2013-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Glucose Area Under the Curve (AUC) Breakfast defines the total exposure to glucose during breakfast. Breakfast is typically considered the most difficult meal to control; low AUC is desirable.This outcome measure was analyzed for each of the three calibration error values (high error, no error and low error). (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 2:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | mmol/l/min (Mean) |
|---|---|
| HIGH Error | 66.8 |
| NO Error | 48.8 |
| LOW Error | 37.4 |
Night-time in target range 5.0-8.33, following the 3 hour controller initialization period blood glucose remained at or near target. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 12:00 AM to 6:00 AM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | percentage of time in target range (Median) |
|---|---|
| HIGH Error | 88 |
| NO Errror | 100 |
| LOW Error | 80 |
Highest and lowest glucose concentrations obtained during breakfast meal. (NCT02065895)
Timeframe: On day #1, day #2 and day #3 (each day could be 24 hours to 7 days apart from prior one, and completed within 6 week period) 8:00 AM to 12:00 PM on day following admission, with samples obtained every 10-15 minutes, for each sequence of calibration errors
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Peak glucose concentration | Nadir glucose concentration | |
| Gain Decreased and Target Increased | 11.3 | 6.6 |
| Gain Increased and Target Decreased | 13.3 | 4.5 |
| Nadir Mean | 11.8 | 4.8 |
1 review available for troglitazone and Diabetes, Gestational
| Article | Year |
|---|---|
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
4 trials available for troglitazone and Diabetes, Gestational
| Article | Year |
|---|---|
Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Double-Blind Method; Female; Gluc | 2002 |
Effect of pioglitazone on progression of subclinical atherosclerosis in non-diabetic premenopausal Hispanic women with prior gestational diabetes.
Topics: Adult; Carotid Artery Diseases; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease | 2008 |
Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; California; Cholesterol, HDL; Cholesterol, LD | 1996 |
Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Glucose Intolera | 2000 |
2 other studies available for troglitazone and Diabetes, Gestational
| Article | Year |
|---|---|
Prediction of type 2 diabetes in women with a history of gestational diabetes using a genetic risk score.
Topics: Adult; Chromans; Diabetes Mellitus, Type 2; Diabetes, Gestational; Disease Progression; Female; Foll | 2013 |
[News on diabetes and public health perspectives].
Topics: Administration, Oral; Adult; Chromans; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitu | 2002 |